• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.调节嵌合抗原受体(CAR)对表皮生长因子受体(EGFR)密度的敏感性可在维持强大抗肿瘤活性的同时限制对正常组织的识别。
Cancer Res. 2015 Sep 1;75(17):3505-18. doi: 10.1158/0008-5472.CAN-15-0139.
2
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice.亲和力优化的ErbB2或EGFR嵌合抗原受体T细胞对小鼠肿瘤的治疗指数有所提高。
Cancer Res. 2015 Sep 1;75(17):3596-607. doi: 10.1158/0008-5472.CAN-15-0159.
3
Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging.用于EGFRvIII表达型胶质瘤过继性免疫治疗的重定向人抗生物素蛋白CAR T细胞及其通过光学成像的评估
Oncotarget. 2015 Sep 15;6(27):23735-47. doi: 10.18632/oncotarget.4362.
4
Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.基于衔接蛋白的嵌合抗原受体 T 细胞工程设计。
Mol Ther. 2017 Nov 1;25(11):2466-2476. doi: 10.1016/j.ymthe.2017.07.009. Epub 2017 Jul 20.
5
Redirecting gene-modified T cells toward various cancer types using tagged antibodies.利用标记抗体将基因修饰的 T 细胞导向各种癌症类型。
Clin Cancer Res. 2012 Dec 1;18(23):6436-45. doi: 10.1158/1078-0432.CCR-12-1449. Epub 2012 Oct 2.
6
Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.利用信使核糖核酸使嵌合抗原受体自我限制表达,将T细胞特异性重定向至表皮生长因子受体。
J Immunother. 2016 Jun;39(5):205-17. doi: 10.1097/CJI.0000000000000126.
7
Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies.用嵌合抗原受体(CAR)修饰细胞因子诱导的杀伤细胞可增强对表皮生长因子受体(EGFR)阳性恶性肿瘤的抗肿瘤免疫力。
Cancer Immunol Immunother. 2015 Dec;64(12):1517-29. doi: 10.1007/s00262-015-1757-6. Epub 2015 Sep 19.
8
Radionuclide therapy using ¹³¹I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression.使用¹³¹I标记的抗表皮生长因子受体靶向纳米颗粒进行放射性核素治疗可抑制由表皮生长因子受体(EGFR)过表达引起的癌细胞生长。
J Cancer Res Clin Oncol. 2016 Mar;142(3):619-32. doi: 10.1007/s00432-015-2067-2. Epub 2015 Nov 16.
9
Masked Chimeric Antigen Receptor for Tumor-Specific Activation.用于肿瘤特异性激活的掩蔽嵌合抗原受体
Mol Ther. 2017 Jan 4;25(1):274-284. doi: 10.1016/j.ymthe.2016.10.011.
10
Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.嵌合受体抗 CD19 或抗 CD38 联合利妥昔单抗的 T 细胞免疫治疗对 B 细胞非霍奇金淋巴瘤的协同和持续作用。
Br J Haematol. 2010 Oct;151(1):37-46. doi: 10.1111/j.1365-2141.2010.08297.x. Epub 2010 Jul 30.

引用本文的文献

1
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer.调节PPARγ信号通路可上调NECTIN4并增强嵌合抗原受体(CAR)T细胞疗法对膀胱癌的疗效。
Nat Commun. 2025 Sep 10;16(1):8215. doi: 10.1038/s41467-025-62710-0.
2
Adoptive cell therapy for cancer: combination strategies and biomarkers.癌症的过继性细胞疗法:联合策略与生物标志物
Front Immunol. 2025 Aug 1;16:1603792. doi: 10.3389/fimmu.2025.1603792. eCollection 2025.
3
Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors.嵌合抗原受体T细胞(CAR-T)疗法在血液系统肿瘤和实体瘤治疗中的当前进展与挑战
Immunotargets Ther. 2025 Jun 27;14:655-680. doi: 10.2147/ITT.S519616. eCollection 2025.
4
B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer.B7-H3和CSPG4共同靶向作为三阴性乳腺癌的泛CAR-T细胞治疗
J Immunother Cancer. 2025 May 26;13(5):e011533. doi: 10.1136/jitc-2025-011533.
5
Generating potent and persistent antitumor immunity via affinity-tuned CAR-T cells targeting mesothelin.通过靶向间皮素的亲和力优化的嵌合抗原受体T细胞(CAR-T细胞)产生强效且持久的抗肿瘤免疫力。
Acta Pharmacol Sin. 2025 May 8. doi: 10.1038/s41401-025-01572-0.
6
SynNotch CAR-T cell, when synthetic biology and immunology meet again.合成Notch嵌合抗原受体T细胞,当合成生物学与免疫学再度相遇时。
Front Immunol. 2025 Apr 16;16:1545270. doi: 10.3389/fimmu.2025.1545270. eCollection 2025.
7
Tailoring CAR surface density and dynamics to improve CAR-T cell therapy.调整嵌合抗原受体(CAR)的表面密度和动力学以改善CAR-T细胞疗法。
J Immunother Cancer. 2025 Apr 29;13(4):e010702. doi: 10.1136/jitc-2024-010702.
8
CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target.嵌合抗原受体(CAR)结合物影响CAR T细胞的基础信号传导、持久性及对靶点的敏感性。
Cancer Immunol Res. 2025 Jun 4;13(6):867-880. doi: 10.1158/2326-6066.CIR-24-1347.
9
Engineering sonogenetic EchoBack-CAR T cells.工程化超声基因回声CAR-T细胞。
Cell. 2025 May 15;188(10):2621-2636.e20. doi: 10.1016/j.cell.2025.02.035. Epub 2025 Apr 2.
10
Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for Immunotherapy.非小细胞肺癌中的肿瘤异质性与免疫反应:免疫治疗的新见解及意义
Cancers (Basel). 2025 Mar 19;17(6):1027. doi: 10.3390/cancers17061027.

本文引用的文献

1
Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.用于胶质母细胞瘤的人源化抗表皮生长因子受体变体III嵌合抗原受体T细胞的合理开发与表征
Sci Transl Med. 2015 Feb 18;7(275):275ra22. doi: 10.1126/scitranslmed.aaa4963.
2
T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells.T细胞受体结合亲和力决定癌症特异性CD8+ T细胞的功能特征。
Clin Exp Immunol. 2015 May;180(2):255-70. doi: 10.1111/cei.12570.
3
Chimeric antigen receptor T cells for sustained remissions in leukemia.用于白血病持续缓解的嵌合抗原受体T细胞。
N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222.
4
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.CBTRUS统计报告:2007 - 2011年在美国诊断出的原发性脑和中枢神经系统肿瘤
Neuro Oncol. 2014 Oct;16 Suppl 4(Suppl 4):iv1-63. doi: 10.1093/neuonc/nou223.
5
Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.异体神经母细胞瘤移植瘤模型中永久性和瞬时性修饰 GD2 嵌合抗原受体 T 细胞对肿瘤控制的性质。
Cancer Immunol Res. 2014 Nov;2(11):1059-70. doi: 10.1158/2326-6066.CIR-14-0051. Epub 2014 Aug 7.
6
Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.通用人工抗原呈递细胞,可选择性扩增表达嵌合抗原受体的 T 细胞,而与特异性无关。
J Immunother. 2014 May;37(4):204-13. doi: 10.1097/CJI.0000000000000032.
7
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.间皮素特异性嵌合抗原受体 mRNA 修饰 T 细胞在实体恶性肿瘤中诱导抗肿瘤活性。
Cancer Immunol Res. 2014 Feb;2(2):112-20. doi: 10.1158/2326-6066.CIR-13-0170.
8
Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.具有分离信号结构域的嵌合抗原受体 T 细胞在体内表现出聚焦的抗肿瘤活性,降低了毒性的潜在风险。
Cancer Immunol Res. 2013 Jul;1(1):43-53. doi: 10.1158/2326-6066.CIR-13-0008.
9
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses.基于 PD-1 和 CTLA-4 的抑制性嵌合抗原受体 (iCARs) 会转移针对其他靶点的免疫治疗反应。
Sci Transl Med. 2013 Dec 11;5(215):215ra172. doi: 10.1126/scitranslmed.3006597.
10
EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects.表皮生长因子受体靶向治疗作为一种生物治疗:了解尼妥珠单抗的临床疗效。
Cancers (Basel). 2011 Apr 18;3(2):2014-31. doi: 10.3390/cancers3022014.

调节嵌合抗原受体(CAR)对表皮生长因子受体(EGFR)密度的敏感性可在维持强大抗肿瘤活性的同时限制对正常组织的识别。

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.

作者信息

Caruso Hillary G, Hurton Lenka V, Najjar Amer, Rushworth David, Ang Sonny, Olivares Simon, Mi Tiejuan, Switzer Kirsten, Singh Harjeet, Huls Helen, Lee Dean A, Heimberger Amy B, Champlin Richard E, Cooper Laurence J N

机构信息

Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas. The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas.

Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

出版信息

Cancer Res. 2015 Sep 1;75(17):3505-18. doi: 10.1158/0008-5472.CAN-15-0139.

DOI:10.1158/0008-5472.CAN-15-0139
PMID:26330164
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4624228/
Abstract

Many tumors overexpress tumor-associated antigens relative to normal tissue, such as EGFR. This limits targeting by human T cells modified to express chimeric antigen receptors (CAR) due to potential for deleterious recognition of normal cells. We sought to generate CAR(+) T cells capable of distinguishing malignant from normal cells based on the disparate density of EGFR expression by generating two CARs from monoclonal antibodies that differ in affinity. T cells with low-affinity nimotuzumab-CAR selectively targeted cells overexpressing EGFR, but exhibited diminished effector function as the density of EGFR decreased. In contrast, the activation of T cells bearing high-affinity cetuximab-CAR was not affected by the density of EGFR. In summary, we describe the generation of CARs able to tune T-cell activity to the level of EGFR expression in which a CAR with reduced affinity enabled T cells to distinguish malignant from nonmalignant cells.

摘要

相对于正常组织,许多肿瘤会过度表达肿瘤相关抗原,如表皮生长因子受体(EGFR)。这限制了经改造表达嵌合抗原受体(CAR)的人类T细胞的靶向作用,因为存在对正常细胞进行有害识别的可能性。我们试图通过从亲和力不同的单克隆抗体生成两种CAR,来产生能够基于EGFR表达密度差异区分恶性细胞与正常细胞的CAR(+) T细胞。具有低亲和力尼妥珠单抗-CAR的T细胞选择性地靶向过度表达EGFR的细胞,但随着EGFR密度降低,其效应器功能减弱。相比之下,携带高亲和力西妥昔单抗-CAR的T细胞的激活不受EGFR密度的影响。总之,我们描述了能够将T细胞活性调节至EGFR表达水平的CAR的产生,其中亲和力降低的CAR使T细胞能够区分恶性细胞与非恶性细胞。